Genome-wide cfDNA liquid biopsy expertise for cancer screening validation and AI-driven biomarker development

GENETON is developing GenoScan LB, a genome-wide liquid biopsy workflow designed for research and validation of minimally invasive cancer screening approaches based on plasma cfDNA analysis. The platform integrates shallow whole-genome sequencing (sWGS), copy-number variation profiling, fragmentomics and interpretable machine-learning models to generate integrated malignancy prediction scores from a single blood draw.

Our expertise covers:

• plasma cfDNA processing and low-depth genome-wide sequencing workflows

• genome-wide CNV and fragmentomic feature extraction

• machine-learning integration of multi-feature cfDNA signals

• longitudinal and screening-oriented biomarker analysis

• study design and validation strategies for multi-cancer screening research

• translational bioinformatics and AI collaboration

• clinical and research partnerships around liquid biopsy implementation

GENETON contributes to international research initiatives including the PREDI-LYNCH consortium, focused on prediction of cancer onset in Lynch syndrome through genome-wide cfDNA analysis and ML-oriented evaluation.

We are interested in collaborations related to:

• multicenter screening studies

• translational oncology research

• investment and commercialization discussions

• EU consortia and Horizon projects